Abstract: Disclosed are a binder solution for an all-solid-state battery including a binder in the form of particles, and a method of manufacturing the same. The binder solution may include a rubber-based binder, a first solvent for dissolving the rubber-based binder, and a second solvent in which the rubber-based binder is insoluble and which is miscible with the first solvent.

Abstract: The present disclosure relates to a binder solution having lithium ion conductivity for an all-solid-state battery and an electrode slurry including the same. Specifically, the binder solution includes a first binder having high binding force, a second binder having higher lithium ion conductivity than that of the first binder, a lithium salt, and an organic solvent that dissolves the lithium salt.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds. When compared with trastuzumab, the antibody of the present disclosure exhibits better killing ability for HER2-unexpressed cancer cells which have non-reactivity (or resistance) to the trastuzumab antibody or have reduced sensitivity. In addition, when the anti-HER2 antibody of the present disclosure is administered in combination with trastuzumab, a synergistic killing ability is achieved for cancer cells on which the trastuzumab antibody acts.

Abstract: The present invention relates to a polypeptide improved in protein purity and in affinity for a target antigen, a conjugate thereof with an antibody or antigen-binding fragment, and a preparation method of the polypeptide and the conjugate. The polypeptide or the conjugate thereof according to the present invention does not undergo glycosylation even when produced in a eukaryotic cell and thus has high protein purity and affinity for a target antigen, showing a very high value as a reagent for diagnosis or treatment of a disease.

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Abstract: The present invention relates to: a novel antibody or an antigen-binding fragment thereof for use in the treatment of cancer by targeting B cell malignancies; a chimeric antigen receptor comprising the same; and uses thereof. The antibody of the present invention is an antibody specifically binding to CD19 highly expressed in cancer cells (particularly, blood cancer) and has very low homology compared to the CDR sequences of conventional CD19 target antibodies, and thus the sequence thereof is unique. In addition, cells expressing a chimeric antigen receptor comprising an anti-CD19 antibody or antigen-binding fragment of the present invention induce immune cell activity in response to a positive cell line expressing CD19, and thus can be usefully used as a therapeutic agent for CAR-immune cells.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19.

Abstract: A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.

Abstract: The present invention relates to a technology which enables a desired shape to be freely represented using sculpture components in a three-dimensional space filled with a transparent material. The present invention is characterized in that, when a sculpture is manufactured by installing, in a three-dimensional space, a text, a picture, a model, and a real object consisting of at least one of points, lines, surfaces, and solids, the shape of the sculpture can be freely represented using a transparent carrier containing at least one of the text, the picture, the model, and the real object, and a transparent carrier serving as a fixing means.

Abstract: A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.

Abstract: The present invention replaces an amino acid residue of a specific region of a parent antibody so as to improve the stability of the antibody, thereby improving druggability. A variant antibody of the present invention, compared to a parent antibody hz1E11, has significantly improved stability while having nearly the same productivity and efficacy. Therefore, the variant antibody of the present invention exhibits, in the development of HER2-specific antibodies, excellent characteristics such as reduction in production costs, inhibition of efficacy reduction and reduction of side effects.

Abstract: The present invention relates to HER2 (Human Epidermal Growth Factor Receptor 2) antibodies to prevent or treat cancers. The antibodies of the invention binds specifically to HER2 over-expressed in cancer cells (particularly, breast cancer and stomach cancer cells), specifically to an epitope on HER2 being different from epitope for trastuzumab. The CDR sequences of the present antibodies exhibit low similarity to CDR sequences of publicly known HER2 antibodies, addressing that the CDR sequences are unique. The antibodies of the present invention in combination with trastuzumab kill cancer cells with significantly enhanced cytotoxicity and therefore very effective in therapy of cancer (particularly, breast cancer and stomach cancer). Without wishing to be bound by theory, the enhanced efficacies of the combined therapy would address that the antibodies of the present invention bind to epitope on HER2 being different from epitope for trastuzumab, and inhibit HER2 in a cooperative manner with trastuzumab.

Abstract: A power supply system is provided. The power supply system includes a power supply system comprises a first rectifier receiving an AC power from a first input AC power source, converting the AC power into a first DC power and outputting the first DC power to a connection node, one or more motors connected in parallel to the connection node, the motors being respectively connected to inverters converting the DC power provided from the connection node into an AC power to control the motors, and an auxiliary power source supplying a second DC power to the connection node when the supply of the first DC power is interrupted, or when an overload of the motors occurs.

Abstract: A combination of a top nozzle and a guide thimble of a nuclear fuel assembly and, more particularly, a structure for joining an inner-extension tube, the top nozzle and the guide thimble. When an inner-extension tube head, which is provided as a means for facilitating removal of the top nozzle of the nuclear fuel assembly from the guide thimble, is removed from an inner-extension tube body to separate the top nozzle from the nuclear fuel assembly, the inner-extension tube body is prevented from undesirably rotating, so that the guide thimble and the inner-extension tube body can maintain the joined state.

Abstract: A power supply system is provided. The power supply system includes a power supply system comprises a first rectifier receiving an AC power from a first input AC power source, converting the AC power into a first DC power and outputting the first DC power to a connection node, one or more motors connected in parallel to the connection node, the motors being respectively connected to inverters converting the DC power provided from the connection node into an AC power to control the motors, and an auxiliary power source supplying a second DC power to the connection node when the supply of the first DC power is interrupted, or when an overload of the motors occurs.

Abstract: A combination of a top nozzle and a guide thimble of a nuclear fuel assembly and, more particularly, a structure for joining an inner-extension tube, the top nozzle and the guide thimble. When an inner-extension tube head, which is provided as a means for facilitating removal of the top nozzle of the nuclear fuel assembly from the guide thimble, is removed from an inner-extension tube body to separate the top nozzle from the nuclear fuel assembly, the inner-extension tube body is prevented from undesirably rotating, so that the guide thimble and the inner-extension tube body can maintain the joined state.

Abstract: A joint structure between a top nozzle and a guide thimble of a nuclear fuel assembly and, more particularly, a structure for joining an inner-extension tube, the top nozzle and the guide thimble. When an inner-extension tube head, which is provided as a means for facilitating removal of the top nozzle of the nuclear fuel assembly from the guide thimble, is removed from an inner-extension tube body to separate the top nozzle from the nuclear fuel assembly, the inner-extension tube body is prevented from undesirably rotating, so that the guide thimble and the inner-extension tube body can maintain the joined state.

Abstract: A method of updating firmware using single optical port communication and a microcontroller (MCU) capable of updating firmware using single optical port communication are disclosed herein. The method includes detecting the voltage of a battery when a firmware update start code is received by a single optical port, transmitting firmware-related information to the transmitter if the detected voltage of the battery is equal to or higher than a predetermined reference voltage, receiving update data corresponding to an update mode, and storing rollback information related to previous version of firmware and also performing an update to new version of firmware in a first mode, and updating the predetermined data of the previous version of firmware using the update data in a second mode.

Abstract: A joint structure between a top nozzle and a guide thimble of a nuclear fuel assembly and, more particularly, a structure for joining an inner-extension tube, the top nozzle and the guide thimble. When an inner-extension tube head, which is provided as a means for facilitating removal of the top nozzle of the nuclear fuel assembly from the guide thimble, is removed from an inner-extension tube body to separate the top nozzle from the nuclear fuel assembly, the inner-extension tube body is prevented from undesirably rotating, so that the guide thimble and the inner-extension tube body can maintain the joined state.